I-O; novel tgts in Multiple Myeloma. KappaMab (MM) Ph 2b, data 1H20. KappaMab Car-T entering clinic 2019. KappaMab & LambdaMab target cell surface proteins KMA and LMA on abnormal plasma cells. KappaMab: complete & partial responses in Ph 1 & 2a. Kappa-mab Car-T entering clinic 2019.
Phase l or ll, Pre-Clinical Stage
Hematology, Immuno-Oncology, Immunotherapy
HaemaLogiX Pty. Ltd
Suite 204, Cicada Innovations, 4 Cornwallis St.
Eveleigh, NSW 2015
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020